Selank

Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in collaboration with the Zakusov Research Institute of Pharmacology, built by extending tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin G heavy chain with known immune-modulating activity, with a Pro-Gly-Pro tripeptide tag. This tag is the same stabilizing modification used in Semax, a related peptide developed by overlapping Russian research groups, and it is intended to slow the rapid enzymatic degradation that limits native tuftsin biological activity to roughly a minute in plasma. In 2009, the Russian Federation Ministry of Health registered Selank as a prescription drug for generalized anxiety disorder and neurasthenia, sold as a 0.15 percent intranasal solution, a genuine and still-current domestic drug approval that distinguishes Selank from purely research-only peptides elsewhere in this queue. No Western regulatory agency, including the FDA or European Medicines Agency, has evaluated or approved Selank for any indication, and outside Russia and a small number of other post-Soviet states it exists only as an unregulated research chemical.

Selank proposed mechanism spans at least three distinct pathways rather than a single clean target. The first is enkephalinase inhibition: in cell-free human serum assays, Selank inhibits the aminopeptidases that degrade enkephalins, endogenous opioid peptides, with an estimated IC50 near 15 micromolar, a mechanism shared with Semax and proposed to potentiate endogenous opioid signaling. The second is GABAergic modulation: Selank has been reported to positively modulate GABA receptor binding and to alter expression of genes involved in GABAergic neurotransmission in both rat brain tissue and cultured human neuroblastoma cells, a mechanism distinct from the classical benzodiazepine binding site and proposed to explain anxiolytic effects without benzodiazepine-like sedation or dependence risk. The third is neurotrophic: intranasal Selank increases brain-derived neurotrophic factor expression in the rat hippocampus, connecting it to the same neurotrophin pathway central to Semax mechanism. Whether these three proposed mechanisms operate independently, sequentially, or through some shared upstream event has not been resolved in the published literature.

The strongest evidence tying this rodent and in vitro mechanism to a human clinical outcome is a 2008 Russian trial that randomized 62 patients with generalized anxiety disorder or neurasthenia to intranasal Selank or the benzodiazepine medazepam. Anxiolytic efficacy, measured on standard psychiatric rating scales, was similar between the two treatments, but selank-treated patients did not experience the sedation associated with medazepam and additionally showed antiasthenic and mild psychostimulant effects; a serum enkephalin-related enzyme activity measure that correlated with baseline symptom severity increased toward normal during selank treatment. This is genuine human evidence in a clinically relevant population and, alongside Semax, places Selank among the peptides in this queue with actual human trial data rather than purely preclinical evidence. It is equally important to state the design plainly: the trial was open-label rather than blinded, used an active comparator rather than a placebo, and enrolled a modest 62 patients, a materially weaker evidentiary standard than the placebo-controlled randomized trials expected of a Western drug approval.

Practically, Selank is used exclusively by the intranasal route, since it is not orally bioavailable and no injectable formulation is in clinical use. Reported side effects in Russian clinical use are generally mild, dominated by local nasal irritation and the psychostimulant-like activation noted in its pivotal trial, without a well-documented pattern of serious systemic toxicity in the limited published literature. Within Russia, Selank is manufactured and prescribed as a regulated pharmaceutical; outside Russia, it is sold under the same name by research-chemical vendors without pharmaceutical manufacturing oversight, and that unregulated product should not be assumed equivalent in purity, potency, or safety to the registered Russian drug used in the clinical trial described here.

Mechanism of Action

Structure and the Tuftsin-Derived Design

Selank is built from tuftsin, a naturally occurring tetrapeptide, Thr-Lys-Pro-Arg, released by enzymatic cleavage of the immunoglobulin G heavy chain and known for immune-modulating activity including enhancement of phagocytosis. Native tuftsin is degraded within roughly a minute in plasma by serum aminopeptidases, sharply limiting its usefulness as a drug. Selank extends the native tuftsin sequence with a Pro-Gly-Pro tripeptide tag, the same stabilizing modification used in Semax, a related peptide developed by overlapping Russian research groups, with the goal of slowing this rapid degradation while retaining a biological activity profile shaped toward anxiolytic and neurotrophic effects rather than tuftsin classical immune functions.

Enkephalinase Inhibition

In cell-free biochemical assays using human serum, Selank inhibits the aminopeptidases responsible for degrading enkephalins, small endogenous peptides that activate opioid receptors, with an estimated IC50 near 15 micromolar. This mechanism, first identified in a combined study of Semax and Selank and later characterized specifically for Selank, is proposed to potentiate endogenous enkephalin signaling, contributing to anxiolytic and antiasthenic effects through a pathway distinct from direct receptor agonism. Whether the degree of enzyme inhibition observed in a cell-free serum assay is achieved within brain tissue after intranasal dosing in a living organism has not been directly established.

GABAergic Modulation

A separate line of evidence points to direct modulation of GABAergic neurotransmission. Selank has been reported to positively modulate GABA receptor binding, and studies in rat brain tissue and in cultured human IMR-32 neuroblastoma cells have found that Selank alters expression of genes involved in GABAergic signaling, in the cell-culture study alongside GABA itself and the antipsychotic olanzapine as comparators. This proposed GABAergic mechanism is distinct from the classical benzodiazepine binding site on the GABA-A receptor, offering a candidate explanation for why Selank produced anxiolytic effects comparable to the benzodiazepine medazepam in its pivotal human trial without the sedation, cognitive slowing, or dependence risk associated with that drug class.

Neurotrophic Signaling

Intranasal Selank administration increases brain-derived neurotrophic factor expression in the rat hippocampus, and in a rat model of chronic ethanol exposure, Selank normalized BDNF content in the hippocampus and prefrontal cortex while preventing the memory and attention deficits that ethanol exposure otherwise produced. This neurotrophic mechanism connects Selank to the same BDNF-TrkB pathway central to Semax proposed mechanism, consistent with the two peptides shared research lineage and shared Pro-Gly-Pro stabilizing tag, though the neurotrophic findings for both peptides remain confined to rodent brain tissue.

Anti-Inflammatory and Immune-Modulating Effects

Reflecting its origin in tuftsin, an immune-signaling peptide, Selank has also been shown to reduce stress-elevated pro-inflammatory cytokines, including IL-1 beta, IL-6, TNF-alpha, and TGF-beta1, in a rat model of social confrontation stress, bringing cytokine levels back toward those of unstressed control animals. This anti-inflammatory effect adds a fourth mechanistic thread to Selank profile, alongside enkephalinase inhibition, GABAergic modulation, and BDNF upregulation, though like the other rodent findings it has not been tested in stressed or anxious human patients.

Clinical Evidence

Generalized Anxiety Disorder and Neurasthenia (Human)

The pivotal human study of Selank randomized 62 patients diagnosed with generalized anxiety disorder or neurasthenia to open-label treatment with intranasal Selank (0.15 percent solution, n=30) or the benzodiazepine medazepam (n=32). Anxiolytic efficacy, assessed with the Hamilton Anxiety Scale, the Zung Self-Rating Anxiety Scale, and Clinical Global Impression, was similar between the two treatment groups over the course of the study. Selank-treated patients did not experience the sedation associated with medazepam and additionally showed antiasthenic (anti-fatigue) and mild psychostimulant effects not seen with the benzodiazepine. A serum biomarker related to enkephalin-degrading enzyme activity, which correlated with symptom duration and severity at baseline, increased toward normal levels during Selank treatment, particularly among the generalized anxiety disorder patients. This is genuine, disease-relevant human evidence, and it is important to state plainly that the trial design was open-label rather than blinded and used an active benzodiazepine comparator rather than a placebo, a materially weaker evidentiary standard than the placebo-controlled trials expected for a Western drug approval.

Human Evidence Gap and Design Limitations

Selank, like Semax from the same Russian research tradition, occupies an intermediate position in this queue’s evidence hierarchy: it has genuine human trial data in a clinically relevant population, a rarity among the research-only peptides here, and a real, decades-old domestic drug registration. At the same time, its only substantial human trial was open-label, non-placebo-controlled, and modest in size, and its proposed mechanisms, enkephalinase inhibition, GABAergic modulation, BDNF upregulation, and cytokine reduction, have each been demonstrated in separate rodent or in vitro studies rather than confirmed together within a single human mechanistic investigation. Readers should treat Selank evidence tier the same way as Semax: more clinical than a purely preclinical research peptide, but well short of the randomized, placebo-controlled, double-blind evidence that supports the small number of FDA-approved peptides elsewhere in this queue.

Safety and Tolerability

Reported side effects of Selank in Russian clinical use are generally mild, with local nasal irritation at the site of intranasal administration being the most commonly reported tolerability issue. The pivotal comparator trial’s key safety finding, an absence of the sedation, cognitive slowing, and dependence potential associated with benzodiazepines, reflects a genuinely favorable comparison, though it should be understood as a comparison against one specific benzodiazepine in one open-label trial rather than a broad safety database. Mild psychostimulant-like activation was also reported and could be experienced as an unwanted effect by some individuals, particularly if dosed later in the day. Systematic adverse-event rate reporting comparable to a modern Western regulatory trial is not available in the published Selank literature.

Regulatory Status

Selank has been a registered prescription drug in Russia since 2009, approved by the Russian Federation Ministry of Health for generalized anxiety disorder and neurasthenia and sold as a 0.15 percent intranasal solution. This constitutes a genuine, ongoing domestic drug approval, distinguishing Selank from purely research-only peptides elsewhere in this queue. No Western regulatory agency, including the FDA or European Medicines Agency, has evaluated or approved Selank for any indication, and it has no approved use anywhere outside Russia and a small number of other post-Soviet states where it is also registered. Outside that registered market, Selank is sold as an unregulated research chemical, typically marketed for anxiety relief or cognitive enhancement, without pharmaceutical manufacturing oversight, quality control, or verified potency. It is not listed by the World Anti-Doping Agency as a specifically prohibited substance, but this reflects its mechanism and regulatory obscurity outside Russia rather than a specific safety clearance for unsupervised use.

Semax versus Selank

Selank and Semax are frequently discussed together because they share a research origin, a Pro-Gly-Pro stabilizing tag, an enkephalinase-inhibiting mechanism, and a proposed BDNF-upregulating effect, but their source molecules, primary marketed indications, and best-supported clinical uses differ. Semax is derived from a fragment of adrenocorticotropic hormone and is registered in Russia primarily for cognitive and stroke-recovery indications, with its largest human trial conducted in post-stroke rehabilitation. Selank is derived from tuftsin, an immune-signaling peptide, and is registered in Russia specifically for generalized anxiety disorder and neurasthenia, with its largest human trial conducted head-to-head against a benzodiazepine in an anxiety-disordered population. Neither peptide’s human trial evidence meets a placebo-controlled, blinded standard, and neither should be assumed interchangeable with the other simply because they share a research lineage and a stabilizing chemical tag.

Dosing Guidance

Within its registered Russian indication, Selank is dosed as a 0.15 percent intranasal solution, administered as drops per nostril multiple times daily over a treatment course of several weeks, the regimen used in the pivotal comparator trial against medazepam in generalized anxiety disorder and neurasthenia. No oral formulation exists, since gastrointestinal degradation would eliminate the peptide before absorption, and intranasal administration is the only clinically studied and registered route; reported alternative-route or higher-dose regimens circulating in research-chemical communities are not the studied or registered protocol and should not be treated as clinically validated. Doses and regimens described here reflect Russian registered prescribing practice and the cited clinical trial, not a protocol independently validated by a Western regulatory trial.